sábado, 14 de novembro de 2026
PesquisarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· June 22, 2026

Will EV Stocks Make a Comeback in 2026?

View original at nasdaq.com
Will EV Stocks Make a Comeback in 2026? In this episode of Motley Fool Hidden Gems Investing, Motley Fool contributors Travis Hoium, Lou Whiteman, and Rachel Warren discuss: Rivian’s R2 launch.The decline of EVs in the U.S.Will autonomy be a value add for EV companies?Hidden gems in the EV market…
Opening lines of the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Rivian is pursuing the R2 with the bill of materials at about half the cost of the R1S, intending it to be a margin driver rather than simply a volume/market-share play.

    60% confidence
  • NXP Semiconductors dominates the automotive processing and battery management systems market with mission-critical microcontrollers required by major global automakers, positioning it as a profitable, diversified beneficiary of ADAS growth.

    60% confidence
  • Hardware redundancy needed for autonomy (LiDAR, dual superchip processors, redundant braking/steering) creates significant capital costs that weigh on corporate profitability and trickle down to consumer prices.

    60% confidence
  • Autonomous driving software faces a 'severe 99% problem' — handling standard highway driving is solvable, but mastering the final 1% of chaotic, unpredictable urban edge cases requires computing power and sophistication that many EV start-ups and automakers cannot reliably deliver on a guaranteed timeline.

    60% confidence
  • QuantumScape's solid-state battery technology, if it can be mass-produced at scale, would be the breakthrough needed to trigger a real EV revolution by enabling more stable, faster-charging batteries.

    60% confidence
  • General Motors' stock has outperformed Rivian, Tesla, Lucid, and QuantumScape over the past three years while trading at just six times forward earnings, suggesting the 'obvious' legacy automaker answer may be the real hidden gem.

    60% confidence
  • Autonomy software is not going to be a meaningful growth avenue that differentiates EV companies from legacy automakers.

    60% confidence
  • Rivian is trying to make the R2 into 'the Subaru of the EV market' by offering a premium, feature-loaded soft-road product at a lower price point.

    60% confidence
  • Secondary market supply of used EVs is very high as early-adopter leased/purchased EVs flood the market, which could drive used EV prices toward parity with gas cars within about five years and may cannibalize new car demand.

    60% confidence
  • Autonomy and driver-assist features will follow the historical pattern of premium features becoming commoditized standard features, as happened with windshield wipers, adaptive cruise control, and leather seats.

    60% confidence
  • It's unclear how much of the EV sales drop-off is due to the end of the tax credit versus early adopters already having bought in and the market not yet being mainstream.

    60% confidence
O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Late-2026 Biotech Catalyst Season: FDA Decisions and Pivotal Readouts Converge Across Oncology, Hepatology and Cardiometabolic
Mid-November 2026 is dense with scheduled biotech catalysts. The ivonescimab BLA PDUFA date is 2026-11-14, the lorundrostat PDUFA date is 2026-12-22, and Phase 3 ECLIPSE hepatitis delta data are due in Q1 2027. Alongside these, siRNA and antibody programs (plozasiran, elebsiran/tobevibart, ianalumab, nipocalimab) reported or presented data at AHA, AASLD, ACR and ASH, while Oryzon advanced iadademstat in AML with Spanish trial authorizations and a planned ALICE-3 Phase III. Late-stage data and regulatory milestones are driving the sentiment. A planned delisting (EGM 2026-11-19, application 2027-01-25) is a separate corporate-structure event with no clear link to the rest.
A nossa leitura dos dados ›
Sinais que acompanhamos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Padrões que observamos ›
Onde as fontes divergem
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,995
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,995 factos verificados com a fonte5,577 documentos-fonte arquivados
Consulte estes dados → isubstrate.com
Will EV Stocks Make a Comeback in 2026? — Source | Via News | pt.VIA.NEWS